Background: Renal cell carcinoma (RCC) has traditionally been considered to be radioresistant. Response rates are believed to be improved by a high dose of stereotactic body radiotherapy (SBRT). A retrospective analysis was conducted of patients treated with SBRT for metastatic disease from RCC.
Material and methods: We reviewed records from 20 patients who underwent SBRT for a total of 30 RCC metastases from 2015 to 2020. Patients were included who had a confirmed primary RCC and radiographic evidence of metastasis, either synchronous or metachronous. The most common SBRT fractionation was 30 Gy in 3 fractions.
Results: Median age was 60 years (range, 40-77 years) and 60% were male. After a median follow-up of 18 months (range, 3-36 months), overall survival was estimated to be 85% and 70%, at 1 and 2 years, respectively, and local control at 2 years was 83.33%. Only 5 patients had documented progression of disease, all of whom received biologically effective dose inferior to 100 Gy, and no patients treated with a higher biologically effective dose had disease, which progressed. The most common acute toxicity was grade 1 fatigue (20%). No grade 3 or higher acute toxicity occurred.
Conclusions: Treatment with SBRT in patients with RCC metastases yielded a high local control rate, promising survival rate, and low toxicity.
Acknowledgments
None.
Statement of ethics
This study has been reviewed and granted exemption approval by the Ethics Committee of our institution University Hospital Ibn Roch. All participants provided consent for their participation and publication of this study. This study was conducted in accordance with relevant ethical standards including the Helsinki Declaration.
Conflict of interest statement
The authors declare that they have no conflicts of interest.
Funding source
None.
Author contributions
All authors of this manuscript have directly participated in planning, execution, and/or analysis of this study.
Data availability
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
| [1] |
Lipworth L, Morgans AK, Edwards TL, et al. Renal cell cancer histological subtype distribution differs by race and sex. BJU Int 2016; 117(2):260-265.
|
| [2] |
Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996; 335(12):865-875.
|
| [3] |
Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med 2017; 376(4):354-366.
|
| [4] |
Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17(8):2530-2540.
|
| [5] |
Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol 2011; 8(6):378-382.
|
| [6] |
De Meerleer G, Khoo V, Escudier B, et al. Radiotherapy for renal-cell carcinoma. Lancet Oncol 2014; 15(4):e170-e177.
|
| [7] |
Wersäll PJ, Blomgren H, Lax I, et al. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother Oncol 2005; 77(1):88-95.
|
| [8] |
Kano H, Iyer A, Kondziolka D, Niranjan A, Flickinger JC, Lunsford LD. Outcome predictors of gamma knife radiosurgery for renal cell carcinoma metastases. Neurosurgery 2011; 69(6):1232-1239.
|
| [9] |
Svedman C, Karlsson K, Rutkowska E, et al. Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney. Acta Oncol 2008; 47(8):1578-1583.
|
| [10] |
Amini A, Altoos B, Bourlon MT, et al. Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: Is RCC truly radioresistant? Pract Radiat Oncol 2015; 5(6):e589-e596.
|
| [11] |
Altoos B, Amini A, Yacoub M, et al. Local control rates of metastatic renal cell carcinoma (RCC) to thoracic, abdominal, and soft tissue lesions using stereotactic body radiotherapy (SBRT). Radiat Oncol 2015;10:218.
|
| [12] |
Hoerner-Rieber J, Duma M, Blanck O, et al. Stereotactic body radiotherapy (SBRT) for pulmonary metastases from renal cell carcinoma—A multicenter analysis of the German working group “Stereotactic Radiotherapy”. J Thorac Dis 2017; 9(11):4512-4522.
|
| [13] |
Zelefsky MJ, Greco C, Motzer R, et al. Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys 2012; 82(5):1744-1748.
|
| [14] |
Stinauer MA, Kavanagh BD, Schefter TE, et al. Stereotactic body radiation therapy for melanoma and renal cell carcinoma: Impact of single fraction equivalent dose on local control. Radiat Oncol 2011;6:34.
|
| [15] |
Agolli L. Stereotactic body radiation therapy could improve disease control in oligometastatic patients with renal cell carcinoma: Do we need more evidence? Ann Transl Med 2019; 7(suppl 3):S105.
|
| [16] |
Kothari G, Foroudi F, Gill S, Corcoran NM, Siva S. Outcomes of stereotactic radiotherapy for cranial and extracranial metastatic renal cell carcinoma: A systematic review. Acta Oncol 2015; 54(2):148-157.
|
| [17] |
Zhang Y, Schoenhals J, Christie A, et al. Stereotactic ablative radiation therapy (SAbR) used to defer systemic therapy in oligometastatic renal cell cancer. Int J Radiat Oncol Biol Phys 2019; 105(2):367-375.
|
| [18] |
Liu Y, Zhang Z, Han H, et al. Survival after combining stereotactic body radiation therapy and tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma. Front Oncol 2021;11:607595.
|
| [19] |
Dengina N, Mitin T, Gamayunov S, Safina S, Kreinina Y, Tsimafeyeu I. Stereotactic body radiation therapy in combination with systemic therapy for metastatic renal cell carcinoma: A prospective multicentre study. ESMO Open 2019; 4(5):e000535.
|
| [20] |
Xie G, Gu D, Zhang L, Chen S, Wu D. A rapid and systemic complete response to stereotactic body radiation therapy and pembrolizumab in a patient with metastatic renal cell carcinoma. Cancer Biol Ther 2017; 18(8):547-551.
|
PDF
(253KB)
